Peijia Medical Ltd. (HK:9996)
:9996
Want to see HK:9996 full AI Analyst Report?
9996 Stock Chart & Stats
HK$6.51
-HK$0.07(-1.80%)
At close: 4:00 PM EST
HK$6.51
-HK$0.07(-1.80%)
Day’s Range― - ―
52-Week RangeHK$4.00 - HK$9.36
Previous CloseN/A
Volume6.00K
Average Volume (3M)1.88M
Market Cap
HK$2.79B
Enterprise ValueHK$2.58B
Total Cash (Recent Filing)HK$610.52M
Total Debt (Recent Filing)HK$434.22M
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.30
Shares Outstanding674,736,940
10 Day Avg. Volume1,295,000
30 Day Avg. Volume1,883,282
Financial Highlights & Ratios
PEG Ratio2.00
Price to Book (P/B)1.95
Price to Sales (P/S)5.04
P/FCF Ratio-11.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$10.33Price Target Upside58.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.01
Revenue Forecast (FY)HK$886.84M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained ~67% gross margins indicate strong unit economics from device sales and consumables. This durable margin buffer supports continued investment in R&D and commercialization while absorbing SG&A scale-up, enabling margin recovery as operating losses decline and procedure volumes grow.
Multi-year Revenue ExpansionConsistent multi-year top-line growth demonstrates product adoption in structural heart and neurovascular markets and builds a foundation for recurring revenue from consumables and delivery systems. Durable revenue scaling strengthens commercial foothold and economies of scale over the next 2–6 months and beyond.
Manageable LeverageLow reported leverage provides financial flexibility while the company transitions toward profitability. Manageable debt reduces near-term refinancing risk and preserves capacity to raise growth capital or fund clinical/commercial initiatives without immediate solvency pressure.
Bears Say
Negative Free Cash FlowMaterial negative free cash flow and ongoing negative operating cash flow indicate persistent cash burn that increases reliance on external financing. This structural cash deficit can dilute shareholders, constrain longer-term R&D and sales investments, and limit runway until sustained cash generation is achieved.
Persistent UnprofitabilityContinued operating losses and a deeply negative net margin show the core business has not yet converted scale into profitability. Until operating leverage improves and fixed costs are absorbed, the company will struggle to self-fund growth and demonstrate sustainable returns to investors.
Negative Returns On EquityNegative ROE signals capital erosion and weak capital efficiency, which can pressure the equity base over time. If returns do not turn positive, the company may need recurring external capital, reducing strategic flexibility and increasing dilution risk for long-term shareholders.
Peijia Medical Ltd. News
9996 FAQ
What was Peijia Medical Ltd.’s price range in the past 12 months?
Peijia Medical Ltd. lowest stock price was HK$4.00 and its highest was HK$9.36 in the past 12 months.
What is Peijia Medical Ltd.’s market cap?
Peijia Medical Ltd.’s market cap is HK$2.79B.
When is Peijia Medical Ltd.’s upcoming earnings report date?
Peijia Medical Ltd.’s upcoming earnings report date is Aug 31, 2026 which is in 78 days.
How were Peijia Medical Ltd.’s earnings last quarter?
Peijia Medical Ltd. released its earnings results on Mar 25, 2026. The company reported -HK$0.218 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.218.
Is Peijia Medical Ltd. overvalued?
According to Wall Street analysts Peijia Medical Ltd.’s price is currently Undervalued.
Does Peijia Medical Ltd. pay dividends?
Peijia Medical Ltd. does not currently pay dividends.
What is Peijia Medical Ltd.’s EPS estimate?
Peijia Medical Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Peijia Medical Ltd. have?
Peijia Medical Ltd. has 674,736,940 shares outstanding.
What happened to Peijia Medical Ltd.’s price movement after its last earnings report?
Peijia Medical Ltd. reported an EPS of -HK$0.218 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.792%.
Which hedge fund is a major shareholder of Peijia Medical Ltd.?
Currently, no hedge funds are holding shares in HK:9996
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Peijia Medical Ltd.
Peijia Medical Limited specializes in the innovation and development of advanced medical devices for transcatheter valve therapies and neurointerventional procedures. Their extensive portfolio of transcatheter valve solutions includes numerous TAVR (transcatheter aortic valve replacement) systems, such as TaurusOne, the retrievable TaurusElite, TaurusNXT (a non-glutaraldehyde dry-tissue system), TaurusApex (featuring polymer leaflets), and Trilogy. For mitral valve interventions, they offer the HighLife transseptal replacement system, SpyderOne (a transapical TMVR system), Sutra for coaptation augmentation, and the GeminiOne edge-to-edge repair system. They also provide the MonarQ and Peijia systems for transcatheter tricuspid valve replacement. Complementary devices supporting these procedures include the TaurusAtlas transfemoral balloon catheter, TaurusExplora pre-shaped guidewire, and introducer sheaths. In the neurointerventional field, Peijia Medical develops devices like the Jasper and Presgo detachable coils (including the Jasper SS variant), various intracranial adjunctive stents such as NeuroStellar, and the SacSpeed balloon dilatation catheter. Additional offerings comprise the Tethys AS aspiration catheter, Syphonet stent retriever, Neway balloon microcatheter, Fluxcap balloon guiding catheter, Presgo microcatheters and micro guidewires, Heralder guiding and distal access catheters, the Tethys intermediate catheter, and the Jasper power supply. Furthermore, the company engages in trading activities. Peijia Medical Limited was founded in 2012 and is headquartered in Suzhou, People's Republic of China.
9996 Stock 12 Month Forecast
Average Price Target
HK$10.33
▲(58.68% Upside)
Technical Analysis
MicroPort Scientific
―
LifeTech Scientific Corporation
―
AK Medical Holdings Ltd.
―
MicroPort CardioFlow Medtech Corp.
―
MicroPort NeuroTech Limited
―
Options Prices
Currently, No data available
---